Avalyn Pharma Overview
- Year Founded
-
2011
- Status
-
Private
- Employees
-
50
- Latest Deal Type
-
Series C1
- Latest Deal Amount
-
$189M
- Investors
-
25
Avalyn Pharma General Information
Description
Operator of a clinical-stage biopharmaceutical company intended for the treatment of idiopathic pulmonary fibrosis and severe respiratory diseases. The company engages in the creation of an inhaled formulation of pirfenidone to increase the amount of drug entering the lungs and decrease side effects and address unmet needs in the treatment of rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs), enabling medical professionals to reduce risks associated with oral treatments, and likely improving efficacy.
Contact Information
Website
www.avalynpharma.comCorporate Office
- 245 First Street
- 18th Floor
- Cambridge, MA 02142
- United States
Corporate Office
- 245 First Street
- 18th Floor
- Cambridge, MA 02142
- United States
Avalyn Pharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Later Stage VC (Series C1) | 22-Sep-2023 | $189M | Completed | Clinical Trials - Phase 2 | ||
| 2. Later Stage VC (Series B) | 24-Apr-2020 | Completed | Clinical Trials - Phase 2 | |||
| 1. Later Stage VC (Series A) | 15-Mar-2017 | $62M | $62M | Completed | Pre-Clinical Trials |
Avalyn Pharma Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Avalyn Pharma Comparisons
Industry
Financing
Details
Avalyn Pharma Competitors (62)
One of Avalyn Pharma’s 62 competitors is viDA Therapeutics, a Venture Capital-Backed company based in Vancouver, Canada.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| viDA Therapeutics | Venture Capital-Backed | Vancouver, Canada | ||||
| Enterprise Therapeutics | Venture Capital-Backed | Brighton, United Kingdom | ||||
| Minerva Neurosciences | Formerly VC-backed | Burlington, MA | ||||
| Artizan Biosciences | Venture Capital-Backed | New Haven, CT | ||||
| BiOrion | Venture Capital-Backed | Groningen, Netherlands |
Avalyn Pharma Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Avalyn Pharma Patents
Avalyn Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023280860-A1 | Nintedanib and nintedanib combination dry powder compositions and uses | Pending | 28-May-2022 | ||
| EP-4531809-A2 | Nintedanib and nintedanib combination dry powder compositions and uses | Pending | 28-May-2022 | ||
| US-20250177294-A1 | Nintedanib and nintedanib combination dry powder compositions and uses | Pending | 28-May-2022 | ||
| CA-3191805-A1 | Nebulizer device optimization for improved aerosol parameters and uses thereof | Pending | 22-Sep-2020 | ||
| EP-4217026-A1 | Nebulizer device optimization for improved aerosol parameters and uses thereof | Pending | 22-Sep-2020 | A61M11/005 |
Avalyn Pharma Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Avalyn Pharma Investors (25)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Catalio Capital Management | Venture Capital | Minority | ||
| Eventide Asset Management | Venture Capital | Minority | ||
| Perceptive Advisors | Venture Capital | Minority | ||
| Angel (individual) | Minority | |||
| Piper Sandler | Investment Bank | Minority |
Avalyn Pharma FAQs
-
When was Avalyn Pharma founded?
Avalyn Pharma was founded in 2011.
-
Where is Avalyn Pharma headquartered?
Avalyn Pharma is headquartered in Cambridge, MA.
-
What is the size of Avalyn Pharma?
Avalyn Pharma has 50 total employees.
-
What industry is Avalyn Pharma in?
Avalyn Pharma’s primary industry is Drug Discovery.
-
Is Avalyn Pharma a private or public company?
Avalyn Pharma is a Private company.
-
What is Avalyn Pharma’s current revenue?
The current revenue for Avalyn Pharma is .
-
How much funding has Avalyn Pharma raised over time?
Avalyn Pharma has raised $287M.
-
Who are Avalyn Pharma’s investors?
Catalio Capital Management, Eventide Asset Management, Perceptive Advisors, , and Piper Sandler are 5 of 25 investors who have invested in Avalyn Pharma.
-
Who are Avalyn Pharma’s competitors?
viDA Therapeutics, Enterprise Therapeutics, Minerva Neurosciences, Artizan Biosciences, and BiOrion are some of the 62 competitors of Avalyn Pharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
